(Q37634350)

21 August 2017

1 reference

title

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

21 August 2017

0 references

1 reference

0 references

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

Mamie H Dong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

Rohit Loomba

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

language of work or name

English

0 references

publication date

1 October 2009

1 reference

21 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

page(s)

893-907

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

15 May 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12325-009-0072-Z

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12325-009-0072-Z

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12325-009-0072-Z

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

12 December 2020

Metformin reverses fatty liver disease in obese, leptin-deficient mice

1 reference

12 December 2020

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

12 December 2020

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

1 reference

12 December 2020

Metformin in non-alcoholic steatohepatitis.

1 reference

12 December 2020

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

1 reference

12 December 2020

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

1 reference

12 December 2020

The prevalence and etiology of elevated aminotransferase levels in the United States

1 reference

12 December 2020

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

12 December 2020

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

12 December 2020

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

12 December 2020

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

12 December 2020

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

12 December 2020

Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery

1 reference

12 December 2020

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

12 December 2020

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

12 December 2020

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

1 reference

12 December 2020

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

12 December 2020

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

12 December 2020

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

12 December 2020

Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

1 reference

12 December 2020

Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement

1 reference

12 December 2020

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

12 December 2020

Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease

1 reference

12 December 2020

Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

1 reference

12 December 2020

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

12 December 2020

Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis

1 reference

12 December 2020

The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions.

1 reference

12 December 2020

PPAR delta as a therapeutic target in metabolic disease.

1 reference

12 December 2020

Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.

1 reference

12 December 2020

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

1 reference

12 December 2020

Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis

1 reference

12 December 2020

Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study

1 reference

12 December 2020

The obesity epidemic: pharmacological challenges

1 reference

12 December 2020

The endocannabinoid system and the control of glucose homeostasis.

1 reference

12 December 2020

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

1 reference

12 December 2020

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

12 December 2020

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

12 December 2020

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

1 reference

12 December 2020

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

1 reference

12 December 2020

Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive

1 reference

12 December 2020

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

1 reference

12 December 2020

Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial

1 reference

12 December 2020

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

1 reference

12 December 2020

PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair

1 reference

12 December 2020

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

1 reference

12 December 2020

Dissecting insulin signaling pathways: individualised therapeutic targets for diagnosis and treatment of insulin resistant states

1 reference

12 December 2020

Thiazolidinediones and fractures in men and women

1 reference

12 December 2020

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

1 reference

12 December 2020

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

1 reference

12 December 2020

Steatohepatitis: a tale of two "hits"?

1 reference

12 December 2020

10.1007/S12325-009-0072-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json

15 May 2020

19921118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6659744&resulttype=core&format=json